Boehringer expands manufacturing facility in Shanghai

German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China.

The expansion will see the installation of an additional bioreactor into the company’s OASIS Shanghai facility.

“We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patients with high quality medicines in China and in the global market’, said Prof Buecheler, Head of Biopharmaceutical Business Unit at Boehringer Ingelheim.

Manufacturing processes are scheduled to begin in 2019. A client’s monoclonal antibody will be the first commercial drug manufactured in the Shanghai facility.

“We look forward to providing our customers with this new source of commercial supply of therapeutic antibodies for their patients,”  Dr. Jiali Luo, General Manager and Site Head of Boehringer Ingelheim Bio China said. “Additionally, we see a growing demand for world-class manufacturing capacities of biologics and are eager to offer our capabilities to local and global customers according to our site supply mission ‘China-for-China’ and ‘China-for-Global’.”

Louis Goss